-
Jan 8, 2025 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoJanuary 8, 2025Author(s):, Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic. It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment. This condition affects a smaller subset of patients with high blood pressure and requires a comprehensive management approach.
-
Jan 8, 2025 | 
consultantlive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
Advancing Hypertension Management: Unmet Needs, Endothelial Dysfunction, and CKD Therapies - Episode 11Published on: , , , Panelists discuss how chronic kidney disease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes blood pressure harder to control. Patient No. 2 has stage 3 CKD and uncontrolled hypertension.
-
Dec 11, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 11, 2024Author(s):, Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic. It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment. This condition affects a smaller subset of patients with high blood pressure and requires a comprehensive management approach.
-
Dec 11, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 11, 2024Author(s):, Antihypertensive drug classes include diuretics, beta-blockers, ACE inhibitors, ARBs, calcium channel blockers, and alpha-blockers, each with distinct mechanisms of action targeting blood pressure regulation. Diuretics reduce blood volume, beta-blockers decrease heart rate, ACE inhibitors and ARBs inhibit the renin-angiotensin-aldosterone system, and calcium channel blockers relax blood vessels.
-
Dec 4, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 4, 2024Author(s):, Traditional antihypertensive drugs often result in variable patient responses and side effects, complicating treatment efficacy and patient adherence. Lifelong administration of these medications can lead to compliance issues, impacting long-term management of hypertension. Current treatments primarily manage symptoms rather than addressing the underlying pathophysiology of hypertension.
-
Dec 4, 2024 | 
consultantlive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
Advancing Hypertension Management: Unmet Needs, Endothelial Dysfunction, and CKD Therapies - Episode 2Current Limitations With Traditional Antihypertensive DrugsPublished on: December 4, 2024Manesh R. Patel, MD, Payal Kohli, MD, FACC, John M. Flack, MD, MPH, FASH, C.
-
Dec 4, 2024 | 
hcplive.com | Manesh R. Patel |Payal Kohli |John Flack |C. Michael Gibson
OpinionVideoDecember 4, 2024Author(s):, Patient adherence to antihypertensive regimens is crucial for effective blood pressure control, with non-adherence leading to suboptimal outcomes and increased health risks. Comorbid conditions like CKD complicate hypertension management, requiring tailored therapeutic approaches and careful monitoring to achieve optimal blood pressure control.
-
Jun 25, 2024 | 
healio.com | Erik Swain |Payal Kohli |Richard Smith
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: HealthyWomen has filed a petition asking the FDA to require changes to the labeling of fenofibrates. The petition states the labeling does not make clear that fenofibrates do not improve CV outcomes.
-
May 20, 2024 | 
onlinelibrary.wiley.com | Michael Khorsandi |Roger S. Blumenthal |Michael Blaha |Payal Kohli
1 INTRODUCTION The 2023 AHA/ACC/Multisociety Guideline for Chronic Coronary Disease (CCD) provides updated recommendations for the management of chronic coronary disease, advocating a much more patient-centered approach incorporating social determinants of health (SDOH). This guideline aims to extend patient survival and enhance quality of life (QoL). This review synthesizes the core perspectives from the 2023 Multi-society guideline on CCD management, highlighting the top take-home messages.
-
Jan 20, 2024 | 
southfloridareporter.com | Payal Kohli |James Roland
Medically reviewed by Dr. Payal Kohli, M.D., FACC — By James RolandA sudden and significant reduction in blood flow to the heart muscle is known as a heart attack, while a similar disruption in circulation to the brain is called a stroke. While both events share some similar symptoms, certain signs of a stroke or heart attack are unique and worth knowing, especially if you or someone close to you has a higher risk of either medical emergency.
